

Table S5.

A.

Target kinase	Cell line	Ligand	Concentration	Duration of stimulation
EGF-R	A431	EGF	50 ng/ml	3 min
FGF-R2	Kato-III	no stimulation		
IGF1-R	MEF	IGF-1	100 ng/ml	3 min
KIT	M07e	SCF	100 ng/ml	3 min
MET	MKN45	no stimulation		
SRC	MEF	no stimulation		
TIE2	CHO	Na-Orthovanadate	10 mM	15 min
VEGF-R2	HUE	VEGF-A	100 ng/ml	3 min
VEGF-R3	MEF	no stimulation		

B.

	IC50 (M)			
Compound	EGF-R	FGF-R2	IGF1-R	KIT
Tasquinimod	>1,05E-05	>1,05E-05	>1,05E-05	>1,05E-05
Lapatinib	1,70E-08	-	-	-
Vargatef	-	1,90E-07	-	-
staurosporine	-	-	2,40E-06	-
Sunitinib	-	-	-	4,10E-10

	IC50 (M)		
Compound	MET	SRC	TIE2
Tasquinimod	>1,05E-05	>1,05E-05	>1,05E-05
PHA665752	3,70E-08	-	-
Dasatinib	-	4,00E-08	-
Sorafenib	-	-	6,30E-07

	IC50 (M)	
Compound	VEGF-R2	VEGF-R3
Tasquinimod	>1,05E-05	>1,05E-05
Sunitinib	2,20E-09	8,90E-09